Grabar Law Office is investigating claims on behalf of shareholders of PROCEPT BioRobotics Corporation (NASDAQ: PRCT).

What is This Investigation About? The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia.

What is Alleged? As alleged in a recently filed securities fraud class action PROCEPT BioRobotics Corporation (NASDAQ: PRCT), through certain of its officers, made materially false and misleading statements and/or failed to disclose materially adverse facts including: (i) that Procept had utilized an extensive discount program designed to incentivize its customers to place bulk orders in excess of procedure demand; (ii) that Procept’s undisclosed discount program had artificially and unsustainably inflated Procept’s reported U.S. handpiece unit sales and revenues by pulling forward sales at the expense of future periods; (iii) that Procept’s undisclosed discount program had caused customer handpiece orders to materially exceed underlying procedure demand throughout the Class Period and that this differential had materially grown over time; (iv) that Procept’s consistent surplus of U.S. handpiece unit sales relative to performed procedures had created a glut of field inventory and overstocking amongst Procept’s customer base, amounting to more than 10,000 excess units by the end of the Class Period; (v) that, as a result of (i)-(iv) above, defendants’ representations regarding Procept’s handpiece unit sales and the utilization of Procept’s field Systems were materially overstated; (vi) that, as a result of (i)-(v) above, Procept was acutely exposed to material undisclosed risks of significant operational and financial harm; and (vii) that, as a result of (i)-(vi) above, Procept was unable to achieve its stated 2025 handpiece sales and revenue guidance and such guidance lacked a reasonably achievable factual basis.

It is further alleged that on August 6, 2025, Procept announced earnings for its second fiscal quarter of 2025, revealing that Procept had only sold approximately 12,750 handpieces in the United States during the quarter.  During Procept’s earnings call, defendant Kevin Waters reported that Procept expected to ship approximately 13,350 units in the following quarter, significantly below consensus estimates of more than 13,840 units.  Procept’s quarterly handpiece sales guidance also implied that Procept would need to grow handpiece sales by approximately 25% year-over-year in the fourth quarter in order to meet Procept’s annual unit sales guidance.  In addition, defendant Reza Zadno revealed that Procept was eliminating the role of Chief Commercial Officer in order to “strengthen” Procept’s “commercial execution.”  On this news, the price of Procept stock fell approximately 16% over a two-day trading period.

Then, on November 4, 2025, Procept announced earnings results for its third fiscal quarter of 2025, revealing that Procept had only sold 13,225 handpieces during the quarter, which missed Procept’s sales guidance issued during the prior quarter.  During the corresponding conference call, defendant Kevin Waters further revealed that Procept was reducing its annual handpiece sales guidance by 1,000 units, down from 53,000 units to 52,000 units to allow for the “optimization of field inventory.”  Defendant Larry L. Wood further admitted that Procept had not “been managing customer inventory by establishing par levels” and that some customers were “probably carrying too much inventory.”  On this news, the price of Procept stock fell more than 10% over a two-day trading period.

Finally, on February 25, 2026, Procept announced earnings results for its fourth fiscal quarter and year ending December 31, 2025.  Procept revealed that handpiece sales had materially exceeded procedures in every quarter since the first fiscal quarter of 2023, a differential which had consistently grown over time, ultimately resulting in cumulative excess field inventory of more than 10,000 units.  Procept further revealed that quarterly handpiece unit sales in the United States had declined significantly from 13,225 units in the third quarter to 9,400 units, representing a sequential decline of nearly 30%.  On this news, the price of Procept stock fell more than 18% over a two-day trading period.

What Can You Do Now? If you purchased PROCEPT BioRobotics Corporation (NASDAQ: PRCT) shares before February 28, 2024, and still hold shares today, you are encouraged to contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085.  You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.

#Procept #PRCT $PRCT